MET Therapies
If you’ve been diagnosed with a MET-altered cancer, there are FDA-approved therapies specifically developed for patients like you. Which therapies may be appropriate depends on which MET alteration you have, your tumor type, your treatment history, and other factors your oncologist will consider.
This page is a starting point for what exists and where to learn more. It is not medical advice, and the right treatment plan for you is one developed with your care team based on your full clinical picture.
If you’re not sure which alteration you have, or if you haven’t had comprehensive biomarker testing yet, start there first.
MET Crusaders can also help you navigate your options directly. Our oncology nursing staff offers one-on-one support to help you understand your results, prepare for conversations with your oncologist, and identify clinical trials or compassionate use programs that may be relevant to your situation. Contact us at info@metcrusaders.org or call 602-618-0183.
Approved MET Drug Therapies
Each MET drug listed below is a link to each therapy’s patient-facing website. For help understanding your options or finding a clinical trial, contact us at info@metcrusaders.org.
Types of MET Drugs
Not all MET drugs work the same way and which ones may be right for you depends on which MET alteration you have.
MET-targeted therapies fall into several categories based on how they work and what they target. Your oncologist will consider your specific alteration, your tumor type, and your treatment history when discussing options with you.
MET TKIs (tyrosine kinase inhibitors) are small-molecule drugs taken orally that block MET signaling from inside cancer cells, preventing them from growing. Tabrecta (capmatinib) and Tepmetko (tepotinib) are the two FDA-approved MET TKIs, both indicated primarily for MET exon 14 skipping.
ADCs (antibody-drug conjugates) use a targeting antibody to deliver chemotherapy directly to cancer cells expressing a specific protein, in this case, MET. Emrelis (telisotuzumab vedotin-tllv) is the FDA-approved MET ADC, indicated for patients with high MET overexpression by IHC.
Bispecific antibodies target two receptors at once. Rybrevant (amivantamab) targets both MET and EGFR and is relevant for patients whose cancer involves both pathways, including some cases of resistance to EGFR inhibitors.
Multi-kinase inhibitors block multiple targets including MET. Xalkori (crizotinib) is in this category and may be used in certain MET-altered cancers.